Robalzotan

Robalzotan
Clinical data

Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name (3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2H-chromene-5-carboxamide
CAS Number	169758-66-1^Y
PubChem CID	3055171
IUPHAR/BPS	72
ChemSpider	2316732^N
UNII	I18M56OGME
Chemical and physical data
Formula	C₁₈H₂₃FN₂O₂
Molar mass	318.174 g/mol
3D model (Jmol)	Interactive image
SMILES C1CC(C1)N(C2CCC2)[C@@H]3CC4=C(C=CC(=C4OC3)F)C(=O)N
InChI InChI=1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)/t13-/m1/s1^N Key:MQTUXRKNJYPMCG-CYBMUJFWSA-N^N
^NY (what is this?)

Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT_1A receptor. It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies. It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT_1A ligands was discontinued. Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.